Ajer Jeffrey Robert's Form 4 filing
Biomarin Pharmaceutical IncBMRN · filed May 6, 2024
- Accession no.
- 0001048477-24-000073
- Filed
- May 6, 2024
- Trade date
- Apr 30-May 2, 2024
- Filing delay
- 6 daysLate
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions. Open-market sales total $414.6K. It was filed 6 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Ajer Jeffrey RobertCIK 0001557533 | Officer (EVP, Chief Commercial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 30, 2024 | Common Stock | AGrant or awardAcquired | +300 | $68.65 | +$20,595 | 71,767 | Direct | |
| May 2, 2024 | Common Stock | SSaleDisposed | −5,000 | $82.91 | −$414,550 | 66,767 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.